Neurocrine signs second deal with big pharma in a week
This article was originally published in Scrip
Executive Summary
Neurocrine Biosciences is to receive $10 million up front from Boehringer Ingelheim as part of an agreement to research and develop small-molecule GPR119 agonists for the treatment of type 2 diabetes.